Instituto de Investigación Sanitaria del Hospital Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Ysengineers S.L., Málaga, Spain.
Appl Clin Inform. 2019 May;10(3):513-520. doi: 10.1055/s-0039-1693426. Epub 2019 Jul 17.
Clinical decision support systems (CDSSs) are a good strategy for preventing medication errors and reducing the incidence and severity of adverse drug events (ADEs). However, these systems are not very effective and are subject to multiple limitations that prevent their implementation in clinical practice.
The objective of this study was to evaluate the effectiveness of an advanced CDSS, HIGEA, which generates alerts based on predefined clinical rules to identify patients at risk of an ADE.
A multidisciplinary team defined the system and the clinical rules focusing on medication errors commonly encountered in clinical practice. Four intervention programs were defined: (1) dose adjustment in renal impairment; (2) adjustment of anticoagulation/antiplatelet therapy; (3) detection of biochemical/hematologic toxicities; and (4) therapeutic drug monitoring. We performed a 6-month observational prospective study to analyze the effectiveness of these clinical rules by calculating the positive predictive value (PPV).
The team defined 211 clinical rules. During the study period, HIGEA generated 1,086 alerts (8.9 alerts per working day), which were reviewed by pharmacists. Fifty-one percent (554/1,086) of alerts generated an intervention to prevent a possible ADE; of these, 66% (368/554) required a documented modification to therapy owing to a real prescription error intercepted. The intervention program that induced the highest number of modifications to therapy was the dose adjustment in renal impairment program (PPV = 0.51), followed by the adjustment of anticoagulation/antiplatelet therapy program (PPV = 0.24). The percentage of accepted interventions was similar in surgical units (68%), medical units (67%), and critical care units (63%).
Our study offers evidence that HIGEA is highly effective in preventing potential ADEs at the prescription stage.
临床决策支持系统(CDSS)是预防用药错误和降低不良药物事件(ADE)发生率和严重程度的有效策略。然而,这些系统的效果并不理想,存在多种限制因素,使其无法在临床实践中得到广泛应用。
本研究旨在评估高级 CDSS HIGEA 的有效性,该系统基于预定义的临床规则生成警报,以识别有发生 ADE 风险的患者。
一个多学科团队专注于临床实践中常见的用药错误,定义了系统和临床规则。定义了四个干预方案:(1)肾功能不全时的剂量调整;(2)抗凝/抗血小板治疗的调整;(3)生化/血液毒性的检测;(4)治疗药物监测。我们进行了为期 6 个月的前瞻性观察研究,通过计算阳性预测值(PPV)来分析这些临床规则的有效性。
团队共定义了 211 条临床规则。在研究期间,HIGEA 生成了 1086 条警报(每个工作日 8.9 条),由药剂师进行审查。生成的警报中有 51%(554/1086)触发了干预措施,以预防可能的 ADE;其中,66%(368/554)因拦截到真实的处方错误而需要对治疗方案进行修改。导致治疗方案修改数量最多的干预方案是肾功能不全时的剂量调整方案(PPV=0.51),其次是抗凝/抗血小板治疗调整方案(PPV=0.24)。在外科病房(68%)、内科病房(67%)和重症监护病房(63%)中,接受干预的比例相似。
我们的研究表明,HIGEA 在预防处方阶段潜在的 ADE 方面非常有效。